Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$1.9 billion.

  • Heron Therapeutics' Retained Earnings fell 70.6% to -$1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 billion, marking a year-over-year decrease of 70.6%. This contributed to the annual value of -$1.9 billion for FY2024, which is 71.25% down from last year.
  • Latest data reveals that Heron Therapeutics reported Retained Earnings of -$1.9 billion as of Q3 2025, which was down 70.6% from -$1.9 billion recorded in Q2 2025.
  • Heron Therapeutics' Retained Earnings' 5-year high stood at -$1.4 billion during Q1 2021, with a 5-year trough of -$1.9 billion in Q3 2025.
  • Its 5-year average for Retained Earnings is -$1.8 billion, with a median of -$1.9 billion in 2023.
  • As far as peak fluctuations go, Heron Therapeutics' Retained Earnings tumbled by 1875.96% in 2021, and later dropped by 4.85% in 2025.
  • Over the past 5 years, Heron Therapeutics' Retained Earnings (Quarter) stood at -$1.6 billion in 2021, then fell by 11.28% to -$1.8 billion in 2022, then dropped by 6.16% to -$1.9 billion in 2023, then fell by 0.71% to -$1.9 billion in 2024, then fell by 0.9% to -$1.9 billion in 2025.
  • Its last three reported values are -$1.9 billion in Q3 2025, -$1.9 billion for Q2 2025, and -$1.9 billion during Q1 2025.